BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced its earnings results on Monday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06), Zacks reports. The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $130.05 million. The firm’s revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 earnings per share.

BioCryst Pharmaceuticals Stock Down 10.0 %

Shares of NASDAQ:BCRX opened at $8.29 on Tuesday. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $9.50. The stock’s 50 day moving average is $8.03 and its 200-day moving average is $7.84.

Analyst Ratings Changes

BCRX has been the subject of several research analyst reports. Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Evercore ISI lifted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.